Memphasys is a listed Australian company (ASX: MEM) that was initially focussed on proprietary electrophoresis and polymer membrane technology. This technology was employed in its first product, the Felix™ device, to enable the separation of sperm from semen. The Felix™ device was developed in conjunction with Distinguished Emeritus Laureate Professor John Aitken and his team at the Priority Research Centre for Reproductive Science at the University of Newcastle, Australia.

Memphasys has subsequently focussed its business development in the artificial reproduction and fertility market. This led to an expanded research partnership with Professor John Aitken and his University of Newcastle team. Memphasys now has a team of seven researchers at the University of Newcastle working on devices, medias, and point-of-care diagnostic products in the field of human and animal reproduction and fertility.

The Felix™ device, a sperm separation technology, is now in commercial production and is available for sale in early access countries for such products. These initial markets include India, Canada, and New Zealand. Clinical studies and preparations of filings for regulatory certifications in China, and Australia, are also underway.